GSK's China Oncology Bet: One Credible Signal, Two Evidence Voids, and a Phase 3 Reckoning Ahead

GSK Accelerates Oncology Pipeline with China Licensing Deals

Since the beginning of 2025, GSK has significantly increased its engagement with China-based drug developers, executing five licensing deals, making it the second most active company in this trend after Roche. These strategic partnerships are primarily focused on acquiring next-generation cancer medicines, including an "antibody-targeted therapy conjugate" from Hutchmed and a "three-pronged myeloma drug" from Chimagen Biosciences. The company's earlier 2023 collaboration with Hansoh Pharma has also yielded a promising oncology asset, recently featured at the World Conference on Lung Cancer, which analysts consider a potentially major future drug.

• GSK has demonstrated a strong strategic focus on China, securing five licensing deals with China-based drug developers since the beginning of 2025. This activity positions GSK as a leader in the industry's broader trend of sourcing novel drug candidates from China, particularly for its oncology pipeline, reflecting a global search for innovative therapies.
• The recent deals have enriched GSK's portfolio with diverse next-generation cancer medicines. Key acquisitions include an "antibody-targeted therapy conjugate" from Hutchmed and an alliance with Chimagen Biosciences for a "three-pronged myeloma drug," showcasing GSK's interest in advanced antibody technology and multi-modal approaches to cancer treatment.
• A drug obtained through a 2023 partnership with Hansoh Pharma is gaining recognition as a significant future asset. Its prominent feature at the World Conference on Lung Cancer and its description by Jefferies analyst Michael Leuchten as an "underappreciated, potentially major oncology asset" highlight its potential to deliver substantial dividends for GSK in the coming years.

Novel Targets Fueling Next-Generation Cancer Medicine Deals

Recent research is expanding the landscape of actionable cancer targets well beyond conventional oncogene inhibition, with particular momentum in immune regulation, protein degradation, and DNA damage response. These emerging modalities are reshaping both drug discovery strategies and the competitive deal environment across oncology.

• VISTA (V-domain Ig Suppressor of T Cell Activation): A novel inhibitory immune checkpoint expressed on myeloid cells, lymphoid cells, and tumoral cells, VISTA substantially regulates innate and adaptive anti-tumoral immune responses within the tumor microenvironment (TME). Evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional checkpoint-based immunotherapy, including cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors.

• T-cell Exhaustion Checkpoints (PD-1, Tim-3, CTLA-4, LAG3, TIGIT): Chronic antigen stimulation within the TME drives T-cell exhaustion — a state characterized by conserved inhibitory receptors, altered transcription and signaling factors, and downregulation of key effector molecules. Exhausted T cells (Tex) have been identified in melanoma, colorectal, and hepatocellular cancers. Strategies to reverse exhaustion include checkpoint inhibitor blockade targeting PD-1, Tim-3, and CTLA-4, combinations of different immune checkpoint therapies (ICTs), and combinations of ICTs with cytokine co-stimulation.

• Cereblon (CRBN) and Targeted Protein Degradation: CRBN, a substrate receptor of the CRL4 E3 ubiquitin ligase complex, is being targeted through novel thalidomide analogs — including avadomide, iberdomide, CC-885, CC-90009, BTX-1188, CC-92480, CC-99282, CFT7455, and CC-91633 — as well as CRBN-based proteolysis targeting chimeras (PROTACs). Both molecular glues and PROTACs stimulate interaction between CRBN and neosubstrates, enabling polyubiquitination and proteasomal degradation of traditionally difficult-to-target proteins such as transcription factors and oncoproteins, with demonstrated activity in hematologic malignancies.

• Cyclin-Dependent Kinases (CDKs) via PROTACs and Molecular Glues: Beyond conventional ATP-competitive inhibition — exemplified by palbociclib, the first FDA-approved CDK4/6 inhibitor — CDK-targeted PROTACs have exhibited improved CDK selectivity in preclinical studies relative to small molecule inhibitors. Molecular glues convert the target protein into a neo-substrate for an E3 ligase, and critically, the efficacy of both PROTACs and molecular glues is tied to ternary complex formation rather than dose, representing a mechanistically distinct therapeutic modality currently represented in over 30 active clinical trials or patient recruitment efforts.

• DNA Damage Response (DDR) Pathway Targets: CRISPR-based screens targeting 365 DDR genes have identified responsive pathways and gene-drug interactions across multiple DDR inhibitor classes. Notably, POLE3/4-deficient cells displayed enhanced sensitivity to an ATR inhibitor, a PARP inhibitor, and camptothecin. Separately, the DDUP microprotein — encoded by the CTBP1-DT lncRNA and upregulated in cisplatin-resistant ovarian cancer — sustains RAD18/RAD51C and RAD18/PCNA complexes at DNA damage sites, driving resistance through dual homologous recombination and post-replication repair mechanisms; ATR inhibition disrupted the DDUP/RAD18 interaction and restored cisplatin hypersensitivity in vivo, identifying DDUP as a potential therapeutic target in platinum-resistant ovarian cancer.

• VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2): Tanibirumab, a fully human monoclonal antibody to VEGFR-2, was evaluated in a Phase I study in patients with refractory solid tumors. The maximum-tolerated dose (MTD) was confirmed at 24 mg/kg, with hemangioma observed in 16 of 26 patients (61.5%) at grade 1–2 severity. Among 18 evaluable patients, no objective response was observed, though 11 patients showed stable disease, and mean trough concentrations exceeded biologically relevant target levels at 12 mg/kg and above.

The Evolving Cancer Treatment Landscape for New Acquisitions

Published trial data from recent years reflects a marked shift in oncology toward biomarker-driven, immunotherapy-based regimens across multiple tumor types. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 and CTLA-4 axes have moved from late-line salvage settings into earlier lines of therapy, including neoadjuvant and adjuvant contexts. In adjuvant renal cell carcinoma, an indirect comparison of nine phase III trials demonstrated that nivolumab plus ipilimumab and pembrolizumab were superior to placebo for disease-free survival, while both tyrosine kinase inhibitors and mTOR inhibitors were inferior — a finding that underscores the growing primacy of ICI-based regimens in curative-intent settings. In triple-negative breast cancer, neoadjuvant pembrolizumab combined with chemotherapy has become standard of care for early-stage II–III disease, with a pathological complete response rate of 58% observed in a real-world cohort, though treatment discontinuation due to adverse events reached 35% and the rate of all-grade immune-related adverse events (61%, with 30% grade 3–5) exceeded that reported in the pivotal KEYNOTE-522 trial.

Molecular subtyping and predictive biomarker integration have become central to treatment selection, particularly in gynecologic and gastrointestinal malignancies. In endometrial carcinoma, mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) have emerged as the most established predictors of ICI benefit, supporting FDA approvals for pembrolizumab and dostarlimab in this subgroup, with clinical trials demonstrating survival benefits for ICI-chemotherapy combinations (e.g., dostarlimab or pembrolizumab plus carboplatin/paclitaxel) in first-line dMMR/MSI-H disease. Similarly, in colorectal cancer, a systematic review of six studies (N = 758) evaluating nivolumab plus ipilimumab in MSI-H/dMMR disease reported objective response rates of 31–69%, durable progression-free survival, and overall survival benefits across disease stages, with grade 3–4 treatment-related adverse events occurring in 14–35% of patients. In gastrointestinal cancers more broadly, hepatocellular carcinoma has seen meaningful progress with combinations such as atezolizumab-bevacizumab and durvalumab-tremelimumab surpassing traditional therapies, while biliary tract cancers have shown modest improvements with durvalumab-chemotherapy combinations.

Beyond checkpoint blockade, the therapeutic armamentarium has expanded substantially through next-generation modalities. In B-cell malignancies, CD20-targeted therapies have evolved from rituximab monoclonal antibodies to antibody-drug conjugates (ADCs), bispecific antibodies — particularly CD20×CD3 constructs that redirect cytotoxic T cells — and CAR-T cell therapies, with agents such as evorpacept and BYON4228 targeting the CD47/SIRPα innate immune checkpoint demonstrating a 50% objective response rate in non-Hodgkin lymphoma when combined with rituximab. In ALK-rearranged NSCLC, the ASCEND-3 phase II study of ceritinib in ALKi-naive, heavily pretreated patients reported a median overall survival of 51.3 months (95% CI: 42.7–55.3) and a median progression-free survival of 16.6 months (95% CI: 11.0–23.2), illustrating the durability achievable with targeted kinase inhibition. In small cell lung cancer, where precision medicine has historically lagged, emerging strategies targeting DLL3 via ADCs, bispecific T-cell engagers, and CAR-T cell therapy, alongside PARP and ATR inhibitors and epigenetic modulators, represent an active frontier, though transformative breakthroughs remain pending further biomarker-selected trial data.

GSK's Strategic Pivot: Unlocking Next-Gen Oncology in China

GSK's recent surge in licensing deals with China-based drug developers marks a clear strategic shift, underscoring a global trend where pharmaceutical giants increasingly look to emerging biotech hubs for innovation. This proactive engagement, particularly in oncology, positions GSK to access a pipeline of next-generation cancer medicines, including advanced modalities like antibody-drug conjugates (ADCs) and trispecific T-cell engagers.

These sophisticated therapies represent a significant leap forward in cancer treatment. ADCs, for instance, offer a highly targeted approach, delivering cytotoxic agents directly to cancer cells, potentially minimizing systemic toxicity and overcoming resistance mechanisms in difficult-to-treat solid tumors like non-small cell lung cancer. Similarly, trispecific T-cell engagers are designed to simultaneously target multiple tumor antigens and activate T cells, promising enhanced tumor binding and more effective eradication of malignant cells, particularly in complex hematological cancers such as multiple myeloma.

However, the promise of these novel modalities comes with inherent risks. The development of T-cell engagers and ADCs is complex, often associated with potential on-target, off-tumor toxicities and significant adverse events like peripheral neuropathy or cytokine release syndrome, necessitating meticulous dose optimization and patient selection. Furthermore, while early data may be promising, the long-term efficacy and safety profiles of these newly acquired assets remain to be fully established in later-stage clinical trials. The oncology landscape is also highly competitive, meaning that even innovative therapies must demonstrate clear differentiation to secure a meaningful market share. GSK's strategy reflects a calculated move to diversify its therapeutic portfolio and address unmet medical needs, but successful integration and navigation of these challenges will be critical for realizing the full potential of these partnerships.